- Home
- LEGH vs CRMD Comparison
LEGH vs CRMD Comparison
Compare LEGH & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LEGH | CRMD |
|---|---|---|
| Founded | 2005 | 2006 |
| Country | United States | United States |
| Employees | 594 | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 495.0M | 876.7M |
| IPO Year | 2018 | 2010 |
Fundamental Metrics
Financial Performance| Metric | LEGH | CRMD |
|---|---|---|
| Price | $20.73 | $11.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | ★ $25.00 | $17.43 |
| AVG Volume (30 Days) | 125.5K | ★ 2.9M |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 1.95 | ★ 2.25 |
| Revenue | $180,497,000.00 | ★ $214,303,672.00 |
| Revenue This Year | N/A | $627.89 |
| Revenue Next Year | $6.07 | $40.95 |
| P/E Ratio | $10.54 | ★ $5.10 |
| Revenue Growth | 10.25 | ★ 1647.67 |
| 52 Week Low | $18.84 | $5.60 |
| 52 Week High | $29.45 | $17.43 |
Technical Indicators
Market Signals| Indicator | LEGH | CRMD |
|---|---|---|
| Relative Strength Index (RSI) | 52.07 | 61.66 |
| Support Level | $19.35 | $10.90 |
| Resistance Level | $20.91 | $12.10 |
| Average True Range (ATR) | 0.68 | 0.50 |
| MACD | 0.27 | 0.24 |
| Stochastic Oscillator | 93.01 | 83.07 |
Price Performance
Historical ComparisonAbout LEGH Legacy Housing Corporation (TX)
Legacy Housing Corp builds, sell, and finance manufactured homes and tiny houses that are distributed through a network of independent retailers and company-owned stores and also sold directly to manufactured home communities. The company also provides financing options to its customers to facilitate the sale of homes.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.